Olon began construction of a GMP facility for biologic APIs in Capua, Italy.
Olon SpA, an API contract development and manufacturing organization (CDMO) and generics supplier, began construction on a new GMP manufacturing facility at its microbial CDMO facility located in Capua, Italy, according to a July 24, 2019 press release.
"I am pleased to announce the start of this GMP capacity expansion just within six months after the acquisition of Capua BioServices. This truly confirms the real opportunity to accelerate growth in Olon's CDMO service positioning and to be recognized as European Leader in the CDMO of microbial fermentation," said Paolo Tubertini, CEO of Olon, in the press release.
The construction of this new GMP facility is associated with a long-term strategic partnership with a large pharmaceutical company. The engineering project is designed to support the manufacture of multiple products, up to commercial scale.
Olon is headquartered in Milan, Italy and has 11 manufacturing facilities in Europe (Italy and Spain), the US (Concord, OH), and India (Mahad).
Source: Olon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.